Abstract: The present invention relates to glycoconjugates containing a sialic acid derivate of general formula (I) and wherein the sialic acid derivate of general formula (I) is conjugated to a mono-, di- or oligosaccharide with up to 40 glycosidically linked, optionally branched sugar residues representing furanose and/or pyranose rings, which are linked N- or O-glycosidically to the polypeptide. The sialic derivatives of general formula (I) are useful for producing pharmaceutical compositions for immunosuppression, cell protection, stimulation of hematopoesis regulation of hormonal secretion and hormonal activation.

Abstract: The present invention features transgenic rodent models for HIV, wherein the transgenic rodent or transgenic rodent cell has incorporated into its genome genes encoding a human CD4 receptor and a human chemokine receptor. In particular the invention relates to transgenic rats, or mice characterized by being susceptible to infection with HIV, capable of expressing HIV structural genes, or HIV replication. The transgenic rodent or rodent cell of this invention is useful for studying the molecular basis of HIV infection, replication and pathogenicity, as well as for the testing of agents for new antiviral or vaccine strategies.

Abstract: The present invention features transgenic rodent models for HIV, wherein the transgenic rodent or transgenic rodent cell has incorporated into its genome genes encoding a human CD4 receptor and a human chemokine receptor. In particular the invention relates to transgenic rats, or mice characterized by being susceptible to infection with HIV, capable of expressing HIV structural genes, or HIV replication. The transgenic rodent or rodent cell of this invention is useful for studying the molecular basis of HIV infection, replication and pathogenicity, as well as for the testing of agents for new antiviral or vaccine strategies.